Global Companion Animal Anti-infectives Market Size By Type (Injection, Unguent), By Application (Dogs, Cats), By Region, And Segment Forecasts, 2023 to 2032

The Global Companion Animal Anti-infectives Market was valued at USD 4.3 billion in 2023 and is projected to reach USD 7.1 billion by 2031, growing at a CAGR of 6.6% during the forecast period from 2023 to 2031. The rising prevalence of zoonotic diseases, growing pet adoption worldwide, and increasing awareness about pet healthcare are key factors propelling market expansion. Anti-infective drugs for companion animals—including antibiotics, antifungals, antivirals, and antiparasitics—are becoming essential in ensuring the health and longevity of pets, including dogs, cats, and small mammals.

Drivers:

1. Surge in Pet Ownership Globally:

The growing trend of humanizing pets has led to increased investments in veterinary care. More pet owners are opting for preventive and therapeutic treatments, significantly driving demand for anti-infective products.

2. Increased Awareness of Zoonotic Disease Prevention:

Rising concern over diseases transmitted from animals to humans has prompted pet owners and veterinarians to emphasize the need for infection control through regular treatments.

3. Advancements in Veterinary Pharmaceuticals:

Innovation in drug formulations and delivery systems, such as palatable oral medications and extended-release injectables, are improving compliance and treatment outcomes in companion animals.

Restraints:

1. Antimicrobial Resistance (AMR):

Misuse and overuse of anti-infectives can lead to AMR, reducing drug efficacy and posing a threat to both animal and human health. This is likely to limit the unrestricted use of certain medications.

2. Regulatory Barriers:

Stringent veterinary drug approval processes and varying regulations across regions may delay the market entry of new products and increase development costs.

Opportunity:

1. Expansion in Emerging Economies:

Countries like India, Brazil, and China are witnessing rapid growth in pet populations and rising disposable incomes, offering untapped potential for anti-infective manufacturers.

2. Rise in E-commerce Veterinary Pharmacies:

Online platforms for purchasing veterinary drugs are gaining traction, making anti-infectives more accessible and enhancing market penetration, particularly in underserved areas.

Market by System Type Insights:

By product type, antibiotics held the largest market share in 2023, owing to their widespread use in treating bacterial infections in companion animals. However, the antiparasitics segment is expected to grow at the fastest rate during the forecast period, driven by an increase in vector-borne diseases and preventive healthcare awareness.

Market by End-use Insights:

In 2023, veterinary hospitals & clinics were the dominant end-use segment, accounting for over 55% of the market. This dominance is attributed to the presence of trained professionals and diagnostic capabilities that facilitate accurate treatment. The home care segment is projected to witness significant growth due to the convenience of administering over-the-counter anti-infective treatments at home.

Market by Regional Insights:

North America emerged as the leading regional market in 2023, fueled by high pet ownership rates, well-established veterinary infrastructure, and supportive insurance coverage for pet treatments. Meanwhile, Asia-Pacific is anticipated to register the highest CAGR through 2031, backed by increasing pet adoption, rising healthcare spending, and growing awareness regarding animal well-being in emerging nations.

Competitive Scenario:

Key players in the Global Companion Animal Anti-infectives Market include Zoetis Inc., Elanco Animal Health, Boehringer Ingelheim International GmbH, Merck Animal Health, Virbac S.A., Ceva Santé Animale, Dechra Pharmaceuticals PLC, Vetoquinol S.A., Bayer AG, and Norbrook Laboratories. Strategic moves such as mergers, acquisitions, and new product launches are common across the competitive landscape:

In 2023, Zoetis launched a long-acting injectable antibiotic for canine respiratory infections.

Elanco expanded its antiparasitic portfolio with chewable tablets targeting fleas and ticks.

Boehringer Ingelheim introduced a novel antiviral therapy for feline infectious peritonitis (FIP) in 2024.

Scope of Work – Global Companion Animal Anti-infectives Market

Key Market Developments:

2023: Zoetis introduced Simparica Trio® into new markets in Southeast Asia, expanding its global footprint.

2024: Elanco launched a co-branded awareness campaign in Europe promoting responsible use of antibiotics.

2025: Dechra Pharmaceuticals acquired a niche veterinary biotech firm focused on antifungal treatments for cats.

FAQs:

1) What is the current market size of the Global Companion Animal Anti-infectives Market?

The market was valued at USD 4.3 billion in 2023.

2) What is the major growth driver of the Global Companion Animal Anti-infectives Market?

The major growth driver is the increasing global pet ownership and the corresponding rise in demand for preventive and curative veterinary care.

3) Which is the largest region during the forecast period in the Global Companion Animal Anti-infectives Market?

North America is expected to remain the largest region throughout the forecast period.

4) Which segment accounted for the largest market share in the Global Companion Animal Anti-infectives Market?

The antibiotics segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Companion Animal Anti-infectives Market?

Major players include Zoetis Inc., Elanco Animal Health, Boehringer Ingelheim, Merck Animal Health, and Virbac S.A.